Provided by Tiger Trade Technology Pte. Ltd.

Quince Therapeutics, Inc.

33.93
+1.825.67%
Post-market: 33.930.00000.00%19:30 EDT
Volume:10K
Turnover:317.02K
Market Cap:34.51M
PE:-0.37
High:34.09
Open:32.77
Low:32.57
Close:32.11
52wk High:909.98
52wk Low:15.10
Shares:1.02M
Float Shares:860.30K
Volume Ratio:0.34
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-90.9250
EPS(LYR):-335.2669
ROE:-153.84%
ROA:-31.51%
PB:-0.98
PE(LYR):-0.10

Loading ...

Company Profile

Company Name:
Quince Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
38
Office Location:
611 Gateway Boulevard,Suite 273,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Directors

Name
Position
Dirk Thye
Chief Executive Officer and Chief Medical Officer and Director
Brigette Roberts
Chief of Corporate Affairs and Director
David A. Lamond
Chairperson of the Board and Director
Christopher J. Senner
Director
June Bray
Director

Shareholders

Name
Position
Dirk Thye
Chief Executive Officer and Chief Medical Officer and Director
Brendan Hannah
Chief Business Officer and Chief Compliance Officer and Chief Operating Officer
Brigette Roberts
Chief of Corporate Affairs and Director
Charles Ryan
President